This message was sent to ##Email##
|
|
|
|
|
AJT
From Aug. 23: The HIV Organ Policy Equity (HOPE) Act, enacted on November 21, 2013, enables research on the transplantation of organs from donors infected with human immunodeficiency virus (HIV) (HIV+) into HIV+ individuals who, prior to transplantation, are infected with HIV.
READ MORE
AJT via Wiley Online Library
From May 31: In accordance with the National Organ Transplant Act and Department of Health and Human Services’ Final Rule, the Scientific Registry of Transplant Recipients (SRTR) publicly releases biannual program‐specific reports that include analyses of transplant centers’ risk‐adjusted waitlist mortality, organ acceptance ratios, transplant rates, and graft and patient survival.
READ MORE
The Transplantation Society
From Aug. 30: Vaccine preventable infections are occurring at epidemic rates both nationally and internationally. At the same time, rates of vaccine hesitancy and refusal are increasing across the country leading to decreased herd immunity. For immunosuppressed transplant recipients, this situation poses great risk.
READ MORE
 |
|
Promoted by
Veloxis Pharmaceuticals
Explore some of the many factors that can put a graft at risk, including CYP3A5*1 expression, declining adherence, and nephrotoxicity. In addition, review pharmacokinetic and clinical data that may be relevant to your practice and patients.
See the Video
|
|
AJT via Wiley Online Library
From May 31: The presence of preformed donor‐specific antibodies in transplant recipients increases the risk of acute antibody‐mediated rejection (AMR). Results of an open‐label single‐arm trial to evaluate the safety and efficacy of eculizumab in preventing acute AMR in recipients of deceased‐donor kidney transplants with preformed donor‐specific antibodies are reported.
READ MORE
American Journal of Transplantation
From Nov. 22: Data for liver transplant recipients regarding the benefit of care concordant with clinical practice guidelines for management of blood pressure are sparse. This paper reports on clinician adherence with BP clinical practice guideline recommendations and whether BP control is associated with mortality and cardiovascular events among LTRs.
READ MORE
Advertisement
Veloxis Pharmaceuticals
Immunosuppressive medications can be a financial burden for kidney transplant patients, potentially costing as much as $10,000 to $14,000 a year. These expenses can have a negative impact on patients’ lives and may play a role in medication nonadherence, which is associated with transplant failure. Learn more about support that is available with a free 30-day trial to allow your patients to start immediately at no cost. And, for patients who are eligible with commercial insurance coverage, a $0 co-pay card offers significant savings.
Find out more
|
American Journal of Transplantation via Wiley Online Library
From March 8: The impact of post-reperfusion syndrome during liver transplantation using donor livers with significant macrosteatosis is largely unknown. Clinical outcomes of all patients undergoing LT with donor livers with Moderate Macrosteatosis between 2000–17 were compared to propensity score matched cohorts of patients undergoing LT with donor livers with Mild Macrosteatosis.
READ MORE
Journal of Hepatology
From June 14: Although there is increasing interest in its use, definitive evidence demonstrating a benefit for postmortem normothermic regional perfusion (NRP) in controlled donation after circulatory death (cDCD) liver transplantation is lacking. The aim of this study was to compare results of cDCD liver transplants performed with postmortem NRP vs. super-rapid recovery (SRR), the current standard for cDCD.
READ MORE
|
|
The New England Journal of Medicine
From May 24: In the context of kidney transplantation, genomic incompatibilities between donor and recipient may lead to allosensitization against new antigens. We hypothesized that recessive inheritance of gene-disrupting variants may represent a risk factor for allograft rejection.
READ MORE
LWW
From Aug. 2: The rs58542926 polymorphism in TM6SF2 (transmembrane 6 superfamily member 2) is a genetic factor predisposing to nonalcoholic fatty liver disease. We aimed to explore the effect of recipient and donor TM6SF2 rs58542926 genotypes on liver graft fat content after liver transplantation.
READ MORE
|
KidneyCare combines clinically validated AlloSure testing with AlloMap kidney and iBox to deliver personalized and Prognostic solutions for transplant patients.
Learn More
|
|
|
|
|
TruGraf® - The 1st and only non-invasive test to rule out “silent" subclinical rejection in stable kidney transplant recipients
The only test to be reimbursed as an alternative to surveillance biopsies
Developed by Clinicians for Clinicians
Learn More
|
|
|
|
|
AJT
From Aug. 16: Acute cellular rejection (ACR) is a significant risk factor for chronic lung allograft dysfunction (CLAD). While clinically‐manifest and higher‐grade (≥A2) ACR is generally treated with augmented immunosuppression, management of minimal (grade A1) ACR remains controversial. In our program, patients with subclinical and spirometrically‐stable A1 rejection (StA1R) are routinely not treated with augmented immunosuppression.
READ MORE
|
Advertisement
Building on the trusted LABScreen Single Antigen platform, ExPlex now offers an extended HLA antibody panel in a single-well setup!
Paired with the original LABScreen SABs, ExPlex provides cutting-edge capabilities with a total of 151 Class I and 119 Class II Common and Well-Documented alleles.
Learn More
|
|
|
|
|
Reach Your Prospects Every Week
Thousands of industry professionals subscribe to association news briefs, which allows your company to push messaging directly to their inboxes and take advantage of the association's brand affinity.
Connect with Highly Defined Buyers and Maximize Your Brand Exposure
|
|
|
|
|
AASLD
From Oct. 4: Among patients with cirrhosis awaiting liver transplantation, prediction of waitlist mortality is adjudicated by Model for End Stage liver disease‐sodium score. Replacing serum creatinine with estimated glomerular filtration rate in the MELD‐Na score may improve prediction of WL mortality, especially for women and highest disease severity.
READ MORE
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
